News - PharmaLink, Dermatologicals

Filter

Current filters:

PharmaLinkDermatologicals

Popular Filters

1 to 25 of 118 results

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

Real world data shows that Stelara offers lower rates of psoriasis infection

Real world data shows that Stelara offers lower rates of psoriasis infection

27-03-2014

New interval findings from an international prospective disease-based registry provide a review of important…

DermatologicalsJanssenPharmaceuticalResearchStelara InjectionUSA

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

New survey confirms psoriasis and psoriatic arthritis patients frequently undertreated or not treated at all

21-03-2014

A unique and extensive survey provides the first-of-its-kind multinational look into the impact psoriasis…

Anti-Arthritics/RheumaticsCelgeneDermatologicalsHealthcarePharmaceutical

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma

18-03-2014

Pierre Fabre Dermatologie has obtained marketing authorization from the US Food and Drug Administration…

DermatologicalsHemangeolNorth AmericaPharmaceuticalPierre FabreRegulationUSA

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

11-03-2014

US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

Nestle takes full control of Galderma Pharma

19-02-2014

The boards of Switzerland-based Nestle, the world’s largest food company, and French cosmetics firm…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceutical

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Bayer’s Diane-35 back on French market

Bayer’s Diane-35 back on French market

16-01-2014

Following the confirmation of the positive benefit-risk profile by the European Medicines Agency, German…

BayerDermatologicalsDiane-35EuropeFranceMarkets & MarketingPharmaceutical

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

NeXeption forms new company, Alexar Therapeutics, to develop novel LXR agonist portfolio

03-01-2014

US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to…

A-110Alexar TherapeuticsDermatologicalsFinancialMergers & AcquisitionsNeXeptionPharmaceuticalResearch

APR and Angelini partner on wound management product

20-12-2013

Privately-held Italian drugmaker Angelini and Switzerland-based health care group Applied Pharma Research…

AmuphaseAngeliniApplied Pharma ResearchDermatologicalsEuropeLicensingNexodynPharmaceutical

Almirall to acquire US dermatology firm for $305 million upfront

Almirall to acquire US dermatology firm for $305 million upfront

17-12-2013

Spain’s largest drugmaker, Almirall says it has reached a definitive agreement to acquire Aqua Pharmaceuticals,…

AlmirallAqua PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceutical

1 to 25 of 118 results

Back to top